Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06222164 · ClinicalTrials.gov registry record
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
A clinical trial of Hematologic Diseases, sponsored by Invivoscribe.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT06222164: Recruiting study of Hematologic Diseases, sponsored by Invivoscribe.
NCT06222164 is a study of Hematologic Diseases that is actively recruiting participants, run by Invivoscribe. The registered enrollment target is 2,000 participants, roughly in line with the 2,120-participant average among 17 other Hematologic Diseases trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06222164, a study of Hematologic Diseases, is actively recruiting participants, sponsored by Invivoscribe.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research
Primary Outcome
N=2000
Conditions Studied
Study Locations (1)
California
- LabPMM - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-03-30 |
| Est. Completion | 2027-06-30 |
What NCT06222164 shows while recruiting
NCT06222164 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,120-participant average among 17 other Hematologic Diseases trials with a reported enrollment target.
The record links to 1 condition, with Hematologic Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT06222164 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06222164 about?
NCT06222164 is a clinical study titled "The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research". Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research
What is the current status of trial NCT06222164?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-03-30. Estimated completion is 2027-06-30.
What conditions does trial NCT06222164 study?
This clinical trial studies the following conditions: Hematologic Diseases.
Who is sponsoring clinical trial NCT06222164?
This trial is sponsored by Invivoscribe, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06222164 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06222164's enrollment target sits among peer trials
2,000 2nd of 17 the highest of 17 other Hematologic Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
RECRUITING · Phase 1
-
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI